Cytori Provides Business Update Along with Top-line Unaudited 2014 Financial Results at the Cowen and Company 35th Annual Health Care Conference in Boston

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided a business and financial performance update in its presentation at the Cowen and Company 35th Annual Health Care Conference in Boston today. The corporate presentation includes certain top-line preliminary unaudited financial results for the quarter and full year ended December 31, 2014 and select performance guidance for the full-year 2015.

• Preliminary cash and debt balances at December 31, 2014 of approximately $14.6 million and $25 million, respectively.
• Preliminary Q4 and full-year 2014 operating cash burn of approximately $4.9 million and $30.3 million; respectively.
• Preliminary Q4 and full-year 2014 product revenue of approximately $2.5 million and $5.0 million, respectively.
• Preliminary Q4 and full-year 2014 contribution (profit/loss) from our sales and marketing organization, excluding share based compensation, of a profit of approximately $44 thousand and a loss of approximately $3.9 million, respectively.
• Preliminary Q4 and full-year 2014 contract revenue of approximately $1.3 million and $2.6 million, respectively.
• Estimation of 2015 operating cash burn of approximately $25 million.
• Full-year 2015 product revenue expected to be within a range from $5 million and $8 million.
• Full-year 2015 contribution (profit/loss) from our sales and marketing organization, excluding share based compensation, expected to be a profit ranging from $100 thousand and $300 thousand.
• Full-year 2015 contract revenue expected to be within a range from $6 million and $8 million.

"During 2014, we were able to combine expense reductions with continued achievement of our business objectives. For example, we reduced our quarterly operating cash burn from a high of $9.2 million in Q2 2014 to $4.9 million in Q4 2014 and restructured our sales and marketing organization to essentially breakeven by Q4 2015," said Dr. Marc H. Hedrick, President and Chief Executive Officer. "Our team has made good progress over the year in a number of areas and the business and interim financial data presented today show more clearly the direction in which we intend to head and our outlook for 2015."

Complete Fourth Quarter and Full-Year 2014 Results

The Company will announce complete financial and operating results of its fourth quarter and the full-year ended December 31, 2014, after the market closes on March 12, 2015. Details to be provided in the upcoming days.

About Cytori Therapeutics, Inc.

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those related to select financial performance guidance are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially.  Some of these risks include clinical and regulatory uncertainties, the challenges inherent in convincing physicians and patients to adopt the new technology, dependence on third party performance, performance and acceptance of our products, and other risks and uncertainties described under the “Risk Factors” in Cytori's Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.